Sequenom, Inc. (NASDAQ:SQNM)

This stock has a very high market potential for the Trisomy 21 market. the molecular diagnostics industry is about a 50 Billion dollar industry and if they have a good product pipeline for this NON-invasive prenatal testing, the sky is the limit. They current have two products in the pipeline, one for RhD and one for Downs.

Downs is a multi billion dollar market worldwide.

TM - neonatal genetics testing. could be huge in the coming years

If you put all of your money in this stock you will do well - its a game changer.

I day traded this stock on June 4 when it began its current climb. Now I wish I had just held on to it because I'd be a lot richer. I'm not very astute on biotech companies, so I'm not quite sure how to rate this one...but my gut tells me it's gonna outperform given how it has fared compared to other biotech companies as of late.

pitch to follow later

Mostly because of gravity. Ha! But seriously biotechnology is a highly volatile industry and this is another example of a company being fueled by insiders purchasing to push the stock higher. It is already over its 52 week range and is bound to fall soon, so as they say, buy hi, short it, and then watch it roll.

Good stuff for great cause, price to high.

finally breaking out due to rise like warm bread dough

why not

A solid, active biotech. Still bleading cash, but plenty remainning, and a steady decrease in burn. This $8 stock was once a darling of the biotech boom, but has been largely forgotten. This is a strong play over the next couple of years, as new, unique, safer, less invasive testing is approved, and new product/patient studies come online. It's been trading in a fairly tight range, (7-11), but look for this one to break out!

gapping up in down market

Similar in some ways to IDEXX Laboratories [IDXX], except with a tighter focus on testing with DNA assays.

What they do:

Sequenom, Inc. provides genetic analysis products and services that translate genomic science into solutions for the biomedical research, molecular medicine, agricultural, and non-invasive prenatal testing markets. Its proprietary MassARRAY system is a high performance nucleic acid analysis platform that measures genetic target material and variations. The MassARRAY system provides results for various DNA analysis applications, including SNP genotyping and allelotyping, quantitative gene expression analysis, quantitative methylation marker analysis, SNP discovery, and oligonucleotide quality control.

The company's customers include clinical research laboratories, biotechnology companies, universities, and government agencies. It has operations in the United States, Europe, and Asia. Sequenom has a strategic collaboration with QIAGEN GmbH to develop a gold-standard preanalytical solution for small molecule DNA enrichment for prenatal diagnostics; and a collaboration and license agreement with Lenetix Medical Screening Laboratory, Inc. to develop and commercialize a proprietary non-invasive prenatal Rhesus D incompatibility test.

...and that represents a whole lot of positive developments being rolled out, or currently in their R&D pipeline. Buy and hold long.

Great up and coming medical products.

Has had a good run lately, but their technology is fundamentally sound and they will continue to rise over the long term.

Life sciences will continue to be at the root of all bio related services and analysis in DNA//RNA determination and monitoring. This stock has shown good progress YTD and has future developments that look promising.

new management, genetic technology pros, and solid new money from investment groups at $3 - SQNM had a

px of $43 (after reverse split 1 for 3) back in the dot com binge era.

I had the pleasure to talk to SQNM's CSO, Dr. Charles cantor. I know SQNM for more than 10 years, but only now they seem to get into the business. The whole sector of genetic testing is going to boom and SQNM are in a very competitive position with their MassArray technology. I bet this to be my personal 5-bagger.

Be valued by more people.

Turnaround opportunity... company used to trade at $30+ per share, dropped to $0.55, went through a reverse stock split and got new management... with new products and exclusive rights to certain markets, these guys are on the rise again